

Board of Governors of the Federal Reserve System, August 5, 2002.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 02-20088 Filed 8-7-02; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Notice

TIME AND DATE: 10 a.m. (EDT) August 19, 2002.

PLACE: 4th Floor, Conference Room, 1250 H Street, NW., Washington, DC.

STATUS: Parts will be open to the public and part closed to the public.

Matters To Be Considered

Parts Open to the Public

1. Approval of the minutes of the July 15, 2002, Board member meeting.

2. Thrift Savings Plan activity report by the Executive Director (with discussion of litigation to be closed to the public).

3. Review of investment policy.

4. Review of Ernst & Young semiannual financial review.

Part Closed to the Public

Discussion of litigation.

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942-1640.

Dated: August 6, 2002.

Elizabeth S. Woodruff,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 02-20263 Filed 8-6-02; 3:33 pm]

BILLING CODE 6760-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS become entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rates determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised quarterly by the Secretary of the Treasury and shall be published

quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 12½% for the quarter ended June 30, 2002. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: July 31, 2002.

George Strader,

Deputy Assistant Secretary, Finance

[FR Doc. 02-20020 Filed 8-7-02; 8:45 am]

BILLING CODE 4150-04-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meeting.

Name: National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

Times and Dates:

8:30 a.m.-4:30 p.m., September 20, 2002.

8:30 a.m.-12 noon, September 21, 2002.

Place: Hyatt Regency, 265 Peachtree Street, N.E., Atlanta, Georgia 30303, telephone 404/577-1234, fax 404/588-3752.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

Purpose: The Secretary is authorized by the Public Health Service Act, section 399H, (42 U.S.C. 280f, as added by Public Law 105-392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to: (1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

Matters To Be Discussed: Discussions will focus on ways the Task Force can collaborate with CDC and other Federal agencies on issues of diagnostic criteria for FAS/Alcohol Related Neurodevelopmental Disorder (ARND) in order to enhance health care providers' recognition of these disorders, and to ensure that those affected and their families receive needed services; the special needs of birth mothers of children with FAS/ARND; a report of the Substance Abuse and Mental Health Services Administration FAS/FAE Center for Excellence on their initial "stakeholders" meetings and future plans; an update on activities from the Interagency Coordinating Committee on Fetal Alcohol Syndrome; new research and program

updates from the CDC; and a discussion of the implementation of the Task Force recommendations by various governmental agencies. Additional agenda items include: Working group updates; discussion of future topics, and scheduling the next meeting.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: R. Louise Floyd, DSN, RN, Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 4700 Buford Highway, NE, (F-49), Atlanta, Georgia 30333, telephone 770/488-7372, fax 770/488-7361.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: August 2, 2002.

John Burckhardt,

Acting Director, Management Analysis and Services Office, , Centers for Disease Control and Prevention.

[FR Doc. 02-20037 Filed 8-7-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Prospective Grant of Exclusive License: Various Retrovirus Isolated From Humans

AGENCY: Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide exclusive license to practice the inventions embodied in the patents and patent applications referred to below to Antibody Systems, Inc., located in Hurst, Texas. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are:

Title: Retrovirus Isolated from Humans, U.S. Patent No. 5,882,912. Issue Date: 03/16/99. CDC Reference No. I-012-97/0; New Spumavirus Isolated from Humans, U.S. Patent Application PCT/US98/02598 dated 2/12/98. CDC Reference No. I-012-97/1; Spumavirus